Adjuvant Imatinib After GIST Surgery: — How Long Is the Course?

Not necessarily. Size alone does not make the decision. What matters is the combination of size, location, mitotic rate, and whether the tumour ruptured. A small gastric GIST with a low mitotic rate and no rupture would typically be classified as low risk and would not require adjuvant treatment. Your oncologist should explain exactly which risk category your tumour falls into and why, so you understand the basis for the recommendation you have been given.

GIST can carry different mutations, and the mutation affects whether imatinib is likely to help. Tumours with a specific PDGFRA mutation — called D842V — do not respond to imatinib, so adjuvant imatinib would not be recommended in that case. Other PDGFRA mutations may still respond. If your pathology report mentions a PDGFRA mutation, ask your oncologist specifically whether it affects imatinib sensitivity and what the plan is if it does.

No — and this is worth knowing before you start. Most people find that nausea, fluid retention, and muscle cramps are most pronounced in the first weeks to months and become more manageable as the body adjusts. They do not stay at the same intensity throughout. If side effects are difficult to live with, tell your team rather than stopping treatment on your own — adjustments to timing, dose, or supportive medicines often make a substantial difference.

Stopping before the recommended period is not advised without discussing it with your oncologist. The three-year recommendation comes from clinical trial evidence showing that a longer course reduces recurrence substantially more than a shorter one. Feeling well during treatment is a sign it is being tolerated, not a signal the course can safely be cut short. If side effects are driving the question, raise that with your team — there are often ways to make treatment more manageable without stopping.

Recurrence during adjuvant imatinib means the disease has become visible again despite the preventive treatment. Your oncologist will assess the location and extent of the recurrence and discuss options, which may include surgery if the recurrence is localised, adjusting imatinib, or changing to another treatment. A recurrence caught on routine surveillance imaging is often still at a stage where further treatment can be effective. Report any new abdominal symptoms promptly rather than waiting for your next scheduled scan.

A few practical points matter. Take imatinib with food and a full glass of water to reduce nausea. Avoid grapefruit and grapefruit juice, which affect how the body processes the medicine. Tell every clinician you see — your GP, dentist, or any other specialist — that you are taking it, because it can interact with common medicines including some antibiotics. If you are considering any herbal supplement or traditional remedy, tell your oncologist first, as some affect imatinib's metabolism in ways that could reduce its effectiveness or increase side effects.